Biologic Medications: A Whole New World
Price: FREE for members and non-members
Session recorded on June 18, 2020
Speaker: John Oppenheimer, MD
Viewers can earn credit by completing the posttest questions
This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.
There is no commercial support for this activity.
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Primary Care Providers
Upon completion of this webinar, the participant should be able to:
- Recognize the heterogeneity of asthma and the appropriate use of biologic agents in this illness
- Recognize the subtypes of chronic sinusitis and the appropriate use of biologic agents in chronic sinusitis with nasal polyposis
- Improve understanding of the heterogeneity of asthma and chronic sinusitis
All identified conflicts of interest have been resolved.
Michael Blaiss, MD, Planner
Disclosures: Consultant/Consulting fee: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
John Oppenheimer, MD, Speaker
Disclosures: Consultant/Consulting fee: AZ, GSK, Novartis and Sanofi
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance